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The magnitude of heat-related deaths during the August 2003
heatwave in France and conflicting discussions about Earth’s
global warming consequences have forced physicians to
revisit an up to now rare disease: classic or environmental
heatstroke (CHS) [1,2]. Indeed, most reported cases of CHS
are sporadic except for a few previously published epidemics
linked to unusual heatwaves [3,4]. The CHS therapeutic
approach to date has therefore been limited to human case
reports or experimental data on animal models.
CHS is often compared with other extreme hyperthermia
syndromes such as malignant hyperthermia and neuroleptic
malignant syndrome, two situations where dantrolene
administration has proved to reduce mortality. It therefore
seemed superficially attractive to study the usefulness of
dantrolene in CHS. The review by Hadad and colleagues
aims to summarize previously published data on dantrolene
use in CHS [5]. Overall, although there are conflicting
results, analysis does not support the use of dantrolene in
this situation. Notably, the few case reports that exhibited a
beneficial effect were not confirmed in controlled studies.
Moreover, heterogeneous study designs make data
interpretation difficult, as dantrolene was used either as a
preventive or curative therapeutic, either on humans or
animals, and either in CHS or exertional heatstroke.
The temptation to use dantrolene in CHS is the result of a
misjudgement about pathophysiology. Dantrolene
effectiveness in malignant hyperthermia does not result from
direct action on the hypothalamic setpoint, but from reducing
muscular heat production. Indeed, as discussed by Hadad
and colleagues, malignant hyperthermia/neuroleptic
malignant syndrome and CHS represent two clinical
hyperthermia entities with quite different heat-generating
pathophysiology: although muscular rigidity is the
cornerstone of heat production in the former, massive
thermoregulatory failure related to prolonged environmental
heat exposure seems to be predominant in CHS [5,6]. So,
although they share a pathognomonic sign (major
hyperthermia), CHS and malignant hyperthermia/neuroleptic
malignant syndrome are two distinct entities with only a few
overlaps concerning heat production mechanisms.
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Abstract
Because they share one pathognomonic sign (major hyperthermia), classic or environmental
heatstroke and malignant hyperthermia have often been confronted from the therapeutic point of
view. As expected and according to major physiopathological discrepancies between both
syndromes, analysis of published data does not support effectiveness of dantrolene in heatstroke
despite its significant reduction in mortality in malignant hyperthermia. If cooling methods still
represent the cornerstone of the heatstroke therapeutic approach, the magnitude of heat-related
deaths and the morbidity associated with the August 2003 French heatwave have highlighted the
need for more ambitious methods of treatment.
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Moreover, there are some arguments against dantrolene use
in CHS. First, dantrolene is known to cause potential hepatic
injury. This is of major concern in the context of CHS, a
disease frequently associated with hepatic failure and/or
disseminated intravascular coagulation [6]. Second, there are
some experimental animal studies reporting negative
inotropic effects of dantrolene on myocardium and
diaphragm muscle [7,8]. As CHS predominantly affects
elderly patients, a population with frequent cardiac
impairment, dantrolene could theoretically be detrimental in
this situation.
After the August 2003 French experience, we were able to
draw several lessons from CHS care. In the first place, the
health care structure appeared to be the cornerstone of
epidemic management and effectiveness. As a delay to
benefit from efficient cooling therapeutics dramatically
influences the immediate prognosis, the most useful action is
undoubtedly to put the patient into the hands of an expert
‘cooling team’ as quickly as possible. In order to initiate
patient cooling earlier, prehospital emergency care (Service
d’Aide Médicale d’Urgence; SAMU) and rescue teams began
to apply ice to the skin of CHS-suffering patients immediately
at the site of care (nursing homes, apartments, public
thoroughfares) until they reached the Emergency
Department. Interestingly, in the study of Bouchama and
colleagues, no difference in the cooling rate could be
demonstrated between the group of patients receiving
dantrolene and the group of patients who did not [9].
However, both treatment groups achieved satisfactory
cooling in less than 1 hour using a body-cooling unit, which
was obviously the key therapeutic procedure in this study [9].
Does that mean that we should only focus on improving our
cooling methods instead of studying adjunctive therapies in
CHS? The answer rests in the mortality rate (20–50%)
attributed to CHS despite active cooling procedures [6].
CHS therapeutic care may benefit from advances in sepsis
management, in that both syndromes share some
pathophysiological similarities: cytokine and acute-phase
protein production, coagulation disorders and, finally,
multiorgan dysfunction [6]. Notably, treatment with
corticosteroids improves prognosis in animal models of
heatstroke, as was reported in patients with septic shock
using low doses of hydrocortisone [10,11]. Similarly,
improvement in knowledge of coagulation disorders
observed in CHS may lead to the indication of replacement
therapy with recombinant activated protein C, as reported in
severe sepsis [12].
Overall, the traumatic experience shared by French
emergency physicians during the August 2003 heatwave,
along with the severe outcome still associated with CHS,
justifies ambitious therapeutic trials. Undoubtedly, Earth’s
global warming will especially expose urban populations to
future heatwaves and thereby to the risk of CHS. If preventive
procedures and identification of vulnerable populations are
crucial, emergency and critical care physicians must take up
the challenge for reducing CHS morbidity and mortality.
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